Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

In its first-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products ...

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment point to continued demand for the healthcare supplies and niche specialty drugs Cencora ...

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a pharmaceutical sourcing and distribution company. With a market cap of approximately $54 billion, Cencora operates through the U.S ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Eli Lilly (Symbol: LLY), Cencora Inc (Symbol: COR), and Royalty Pharma plc (Symbol: RPRX) will all trade ex-dividend for ...

In this article, we are going to take a look at where Cramer noted that while Cencora, Inc. (NYSE:COR) stands against other stocks that Jim Cramer discussed recently. On Wednesday’s episode of ...

LONDON - Cencora, Inc., a company whose securities are listed on the New York Stock Exchange, has concluded a post-stabilisation period without any stabilisation activities being conducted ...

NEW YORK - J.P. Morgan Securities plc has announced that it may take actions to stabilize the market price of Cencora, Inc.’s newly offered securities, which include EUR 3-year and 7-year fixed ...